SCHEMBL21591747

SCHEMBL21591747

COc1cc(CCNC(=O)OC(C)(C)C)c(CCO)cn1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MTNR1B P49286 5/20 0.46
MTNR1A P48039 4/20 0.46
NQO2 P16083 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
STK17B O94768 1/20 0.38
STK17A Q9UEE5 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GFER P55789 1/20 0.38
AAK1 Q2M2I8 1/20 0.38
DYRK1A Q13627 1/20 0.37
MAPT P10636 1/20 0.37
POLB P06746 1/20 0.37
IDO1 P14902 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21591739 0.85 MTNR1B (0.41) MTNR1BMTNR1ANQO2HTTNPSR1
SCHEMBL23854684 0.84 MTNR1B (0.46) MTNR1BMTNR1ANQO2TDP1HTT
SCHEMBL21591748 0.84 MTNR1B (0.50) MTNR1BMTNR1AMAPT
SCHEMBL30570606 0.83 MTNR1B (0.48) MTNR1BMTNR1ANQO2TDP1HTT
SCHEMBL23854724 0.83 MTNR1B (0.48) MTNR1BMTNR1ANQO2TDP1HTT
SCHEMBL23854682 0.82 MTNR1B (0.45) MTNR1BMTNR1ANQO2TDP1HTT
SCHEMBL28517134 0.82 MTNR1A (0.41) MTNR1BMTNR1ANQO2TDP1HTT
SCHEMBL21594070 0.81 MTNR1B (0.42) MTNR1BMTNR1ANQO2TDP1HTT
SCHEMBL3944673 0.81 AAK1 (0.39) MTNR1BMTNR1AALDH1A1AAK1MAPT
SCHEMBL21591730 0.79 NPC1 (0.43) MTNR1BMTNR1ANQO2HTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3807270-A1 NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2021-04-21 EP disclosed
WO-2019238616-A1 NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2019-12-19 WO disclosed